| Generic name | Pegaspargase |
| Pronunciation | peg-AS-par-jase |
| Brand name(s), other common name(s) | Oncaspar®, PEG-L-asparaginase |
| Drug type | Enzyme that prevents cancer cells from surviving |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).
Side effects needing medical attention
Abdominal or stomach pain; blurry vision; constipation; dry mouth and skin; fatigue; increased hunger or thirst; increased need to urinate; nausea; rash; unexplained weight loss; vomiting.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.